Manufacturer of Controlled Substances; Notice of Application, 82073 [2010-32855]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 249 / Wednesday, December 29, 2010 / Notices
Consent_Decrees.html. A copy of the
proposed consent decree may also be
obtained by mail from the Consent
Decree Library, P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611 or by faxing or e-mailing a
request to Tonia Fleetwood
(tonia.fleetwood@usdoj.gov), fax no.
(202) 514–0097, phone confirmation
number (202) 514–1547. In requesting a
copy from the Consent Decree Library,
please enclose a check in the amount of
$28.75 (25 cents per page reproduction
cost) payable to the U.S. Treasury or, if
by e-mail or fax, forward a check in that
amount to the Consent Decree Library at
the stated address.
Maureen M. Katz,
Assistant Chief, Environmental Enforcement
Section, Environment and Natural Resources
Division.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 28, 2011.
Dated: December 20, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–32855 Filed 12–28–10; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2010–32661 Filed 12–28–10; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Federal Bureau of Prisons
Drug Enforcement Administration
Notice of Intent To Prepare a Draft
Environmental Impact Statement
Manufacturer of Controlled
Substances; Notice of Application
AGENCY:
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 3, 2010,
Siegfried (USA), 33 Industrial Park
Road, Pennsville, New Jersey 08070,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
srobinson on DSKHWCL6B1PROD with NOTICES
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Glutethimide (2550) ......................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oxymorphone (9652) ...................
Oxycodone (9143) ........................
02:10 Dec 29, 2010
Notice of Intent to Prepare a
Draft Environmental Impact Statement
(DEIS) for development of a Federal
Correctional Institution and Federal
Prison Camp by the U.S. Department of
Justice, Federal Bureau of Prisons
(BOP). Land under consideration for
development consists of areas located
on BOP-owned property comprising the
U.S. Penitentiary (USP) in Leavenworth,
Kansas.
SUMMARY:
I
Background
I
II
II
II
II
II
II
II
II
II
II
II
II
II
The Federal Bureau of Prisons (BOP)
is responsible for carrying out
judgments of the federal courts
whenever a period of confinement is
ordered. The mission of the BOP is to
protect society by confining offenders in
the controlled environments of prisons
and community-based facilities that are
safe, humane, cost-efficient and
appropriately secure, and that provide
work and other self-improvement
opportunities to assist offenders in
becoming law-abiding citizens.
The BOP is facing continuous growth
in the number of federal inmates with
projections showing the federal inmate
population increasing from 210,227
inmates at the end of fiscal year 2010 to
over 226,000 inmates by the end of
fiscal year 2013. As such, the demand
for bedspace within the federal prison
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
VerDate Mar<15>2010
Federal Bureau of Prisons, U.S.
Department of Justice.
ACTION: Notice of intent to prepare a
draft environmental impact statement.
Jkt 223001
PO 00000
Frm 00109
Fmt 4703
Sfmt 4703
82073
system continues to grow at a significant
rate. At the present time, the federal
inmate population exceeds the
combined rated capacities of the
existing 116 federal correctional
facilities.
The federal inmate population has
grown dramatically over the past two
decades. While the BOP is no longer
experiencing the dramatic population
increases of between 10,000 and 11,000
inmates per year that occurred from
1998 to 2001, the increases are still
significant and a net growth of over
6,000 inmates is projected for FY 2011
and 5,600 is projected for FY 2012. The
federal inmate population is projected
to increase and continue to exceed the
rated capacity of the BOP’s 116
institutions and current contract
facilities. Currently, the BOP is 36
percent above rated capacity systemwide in the federal prison system, 43
percent over rated capacity at medium
security facilities, and 53 percent over
rated capacity at high security
institutions. As in the past, the BOP will
continue to increase the number of beds
through additional contract beds,
acquisition and adaptation of existing
facilities, and new prison construction
as funding permits. Adding capacity
through these various means, allows the
BOP the opportunity to work towards
keeping prison crowding at manageable
levels to ensure both public safety and
the safety of inmates within the BOP
institutions.
In the face of the continuing increase
in the federal prison population, one
way the BOP has expanded its capacity
is through construction of new
institutions. As part of this effort, the
BOP has a facilities planning program
featuring the identification and
evaluation of sites for new facilities. The
BOP routinely identifies prospective
sites that may be appropriate for
development of new federal correctional
facilities determined by the need for
such facilities in various parts of the
country and the resources available to
meet that need.
The BOP routinely screens and
evaluates private and public properties
located throughout the nation for
possible use and development. Over the
past decade, the BOP has examined
prospective sites for new correctional
facilities development in Alabama,
Kentucky, New Hampshire, Arizona,
Mississippi, West Virginia, California
and other locations around the country
and has undertaken environmental
impact studies in compliance with the
National Environmental Policy Act of
1969, as amended.
E:\FR\FM\29DEN1.SGM
29DEN1
]]>Agencies
[Federal Register Volume 75, Number 249 (Wednesday, December 29, 2010)]
[Notices]
[Page 82073]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-32855]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on November 3, 2010, Siegfried
(USA), 33 Industrial Park Road, Pennsville, New Jersey 08070, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)........... I
Dihydromorphine (9145)..................... I
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
Glutethimide (2550)........................ II
Codeine (9050)............................. II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
Oxymorphone (9652)......................... II
Oxycodone (9143)........................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than February 28, 2011.
Dated: December 20, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-32855 Filed 12-28-10; 8:45 am]
BILLING CODE 4410-09-P
